- Home
- PAYS vs LPTX Comparison
PAYS vs LPTX Comparison
Compare PAYS & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYS
- LPTX
- Stock Information
- Founded
- PAYS 2001
- LPTX 2011
- Country
- PAYS United States
- LPTX United States
- Employees
- PAYS N/A
- LPTX N/A
- Industry
- PAYS Business Services
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAYS Consumer Discretionary
- LPTX Health Care
- Exchange
- PAYS Nasdaq
- LPTX Nasdaq
- Market Cap
- PAYS 125.2M
- LPTX 119.6M
- IPO Year
- PAYS 1998
- LPTX N/A
- Fundamental
- Price
- PAYS $4.45
- LPTX $0.38
- Analyst Decision
- PAYS Strong Buy
- LPTX Buy
- Analyst Count
- PAYS 4
- LPTX 2
- Target Price
- PAYS $6.56
- LPTX $8.00
- AVG Volume (30 Days)
- PAYS 403.0K
- LPTX 283.3K
- Earning Date
- PAYS 05-08-2025
- LPTX 05-13-2025
- Dividend Yield
- PAYS N/A
- LPTX N/A
- EPS Growth
- PAYS N/A
- LPTX N/A
- EPS
- PAYS 0.11
- LPTX N/A
- Revenue
- PAYS $63,792,627.00
- LPTX N/A
- Revenue This Year
- PAYS $25.98
- LPTX N/A
- Revenue Next Year
- PAYS $14.22
- LPTX N/A
- P/E Ratio
- PAYS $40.62
- LPTX N/A
- Revenue Growth
- PAYS 26.77
- LPTX N/A
- 52 Week Low
- PAYS $1.80
- LPTX $0.22
- 52 Week High
- PAYS $5.59
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- PAYS 79.28
- LPTX 48.68
- Support Level
- PAYS $3.31
- LPTX $0.35
- Resistance Level
- PAYS $4.58
- LPTX $0.40
- Average True Range (ATR)
- PAYS 0.30
- LPTX 0.04
- MACD
- PAYS 0.10
- LPTX 0.00
- Stochastic Oscillator
- PAYS 92.86
- LPTX 53.70
About PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .